TOP NEWS
CALL to participate in IPA Project Every Move Counts
At International Pompe Day the International Pompe Association kicked off the Every Move Counts project. This project focuses on raising awareness of the importance of movement. We all have different abilities and levels of disability, but the important thing to...
OTHER NEWS
Statement from Genzyme and Pharming
Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More that can be made available to the greatest number of patients in the shortest possible time. As part of this commitment,...
Results of First 36 Weeks of Treatment in Infants in Netherlands Published
The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den Hout, Arnold J J Reuser, Arnold G Vulto, M Christa B Loonen, Adri Cromme-Dijkhuis, Ans T Van der Ploeg Following is a short...
Genzyme General Obtains Rights to Pompe Disease Therapy from Synpac
Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 - Genzyme General and Synpac (North Carolina) today announced an agreement under which Genzyme will obtain exclusive, worldwide rights...
Pharming’s first Phase II clinical trial for Pompe’s disease finalised
Pharming’s first Phase II clinical trialA research study that tests new treatments or approaches in people. More for Pompe’s disease finalised, showing survival, skeletal muscleMuscles that control movement and are commonly affected in Pompe disease. More regeneration and overall improvement of heart and lung functions Leiden, the Netherlands, March 15, 2000 The bio-pharmaceutical company Pharming Group N.V....
Enzyme Replacement Therapy (ERT), Gene Therapy Diet, Ephedrine, and Exercise Study
New York University Medical Center Frank Martiniuk, Ph.D. A collaborative effort to test animal models with enzymeA protein that helps the body carry out chemical reactions. More and gene replacement is underway. Dr. Martiniuk is sending the human gene and acid a-glucosidase to Australia to be tested in March on cattle affected by...
Systemic correction of the muscle disorder glycogen storage disease type II
Applied Biological Sciences Systemic correction of the muscle disorder glycogen storage disease type IIThe scientific name for Pompe disease, based on how glycogen builds up in the body. More after hepatic targeting of a modified adenovirus vectorA delivery system, often based on a modified virus, used to carry genetic material into cells. More encoding human acid alpha glucosidase….......... National Academy of Sciences Vol. 96, Issue 16, 8861-8866,...
Duke Scientists Reverse a Rare Form of Muscular Dystrophy in Mice Using Gene Therapy
News Release by Karyn Hede Duke Medical Center News Office August 2, 1999 Using a modified virus to deliver a therapeutic gene, scientists at Duke University Medical Center have shown that, in mice, they can reverse the damage caused by an inherited muscle-wasting...
First IPA Conference Held July 2-4, 1999
The first IPA Conference was held on July 2-4, 1999, in Naarden, the Netherlands. The meeting was attended by over 60 participants from 11 countries which included members of the medical and scientific community, patient organizations and industry. Presentations...
Duke University Starts Clinical Trials for Pompe’s Disease
The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 The following status statement was released by Synpac (North Carolina), Inc., on June 30, 1999 Synpac Pharmaceuticals Limited Cambois, Bedlington, Northumberland NE22 7DB...
Modified Adenovirus for GSD-II
The following article by Laura Spinney appears in BioMednews Reports (6- 25-99,#57) Glycogen storage disease type IIThe scientific name for Pompe disease, based on how glycogen builds up in the body. More causes enlargement of certain muscles, particularly the heart and tongue, due to their inability to break down glycogenA stored form of sugar used for energy. More. A team of American scientists...
Acid Maltase Deficiency Association
For the AMDA videos: All Rights reserved. No part of the AMDA's videos may be reproduced or transmitted in any form or by any means, electronic or mechanical, without the written permission of the copyright holder.
If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:
info@amda-pompe.org
THE AMDA
PO Box 700248
San Antonio, Texas 78270 USA